Insight Molecular Diagnostics Inc. (IMDX) stock
IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$1.78−0.08 (-4.30%)
Close on Nov 17, 2026Market cap $58.25MP/E –Yield –
Insight Molecular Diagnostics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Insight Molecular Diagnostics's ebitda for the twelve months ending Jun 30, 2026 was -$47.86M. For fiscal 2025 it was -$48.93M. The highest annual figure on record is -$16.47M in fiscal 2022.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$48.93M | – |
| FY2024 | Dec 31, 2024 | -$59.48M | – |
| FY2023 | Dec 31, 2023 | -$23.46M | – |
| FY2022 | Dec 31, 2022 | -$16.47M | – |
| FY2021 | Dec 31, 2021 | -$52.93M | – |
| FY2020 | Dec 31, 2020 | -$29.40M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$10.74M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.78M | – |
| Q4 FY2025 | Dec 31, 2025 | -$22.87M | – |
| Q3 FY2025 | Sep 30, 2025 | -$10.46M | – |
| Q2 FY2025 | Jun 30, 2025 | -$9.28M | – |
| Q1 FY2025 | Mar 31, 2025 | -$6.31M | – |
| Q4 FY2024 | Dec 31, 2024 | -$33.06M | – |
| Q3 FY2024 | Sep 30, 2024 | -$13.18M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.31M | – |
| Q1 FY2024 | Mar 31, 2024 | -$8.93M | -241.8% |
| Q4 FY2023 | Dec 31, 2023 | -$15.79M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.11M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.86M | – |
| Q1 FY2023 | Mar 31, 2023 | $6.30M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.22M | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.32M | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.24M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.73M | – |
| Q4 FY2021 | Dec 31, 2021 | -$35.46M | – |
| Q3 FY2021 | Sep 30, 2021 | -$13.35M | – |
| Q2 FY2021 | Jun 30, 2021 | -$13.36M | – |
| Q1 FY2021 | Mar 31, 2021 | -$11.24M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.37M | – |
See a number that looks wrong?